Advanced Search
0
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018
  • Products Id :- GMDHC10638IDB
  • |
  • Pages: 107
  • |
  • |
  • Region:
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 6, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome-Overview

Acute Respiratory Distress Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome-Companies Involved in Therapeutics Development

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Hydra Biosciences Inc

Implicit Bioscience Ltd

PaxVax Inc

ProMetic Life Sciences Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome-Drug Profiles

Aerosurf-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-10901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1037-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2586881-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multistem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5093-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5188-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simvastatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCP-25-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome-Dormant Projects

Acute Respiratory Distress Syndrome-Discontinued Products

Acute Respiratory Distress Syndrome-Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Faron Pharmaceuticals: Traumakine biomarker analysis of the Phase III INTEREST trial

May 11, 2018: Faron Pharmaceuticals : Update on the Phase III INTEREST trial of Traumakine in the treatment of ARDS

May 08, 2018: Faron announces top line data from the Phase III INTEREST trial with Traumakine in the treatment of ARDS

Feb 05, 2018: Faron establishes second Traumakine manufacturing site

Jan 29, 2018: FDA grants Fast Track Designation to Faron for Traumakine

Jan 24, 2018: FDA has approved Faron's Traumakine IND

Dec 11, 2017: The patient recruiting of the Traumakinen INTEREST study has ended

Dec 01, 2017: Appointment of Chief Commercial Officer

Oct 02, 2017: Farons Traumakine Receives Promising Innovative Medicine Designation from the MHRA for the Treatment of ARDS

Sep 04, 2017: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine following completion of European and Japanese Phase III studies

Aug 04, 2017: Faron Pharmaceuticals: IDMC recommends Traumakine Phase III ARDS study to continue as planned

May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC

Apr 25, 2017: Navigen Announces USD1.7MM Phase II NIH SBIR Award to Support the Development of ARF6 Inhibitors for Treatment of Acute Lung Injury

Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation

Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Athersys Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Bayer AG, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Cells for Cells SA, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Commence Bio Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by CompleGen Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Cynata Therapeutics Ltd, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Faron Pharmaceuticals Oy, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by GlaxoSmithKline Plc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Hydra Biosciences Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Implicit Bioscience Ltd, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by PaxVax Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by ProMetic Life Sciences Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Savara Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by SolAeroMed Inc, H2 2018

Acute Respiratory Distress Syndrome-Pipeline by Windtree Therapeutics Inc, H2 2018

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2018

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2018 (Contd..1), H2 2018

Acute Respiratory Distress Syndrome-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Hydra Biosciences Inc

Implicit Bioscience Ltd

PaxVax Inc

ProMetic Life Sciences Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment
select a license
Single User License
USD 2000 INR 140000
Site License
USD 4000 INR 280000
Corporate User License
USD 6000 INR 420000
NEWSLETTER BY CATEGORY
FAQ
Clientele
Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...
Related Products in vertical
Company
Quick links
Other Links
Contact Us
Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

apply for job

Engage with Us

sales [@] kenresearch.com

  • Master Card
  • Visa Card
  • American Card

© Copyright 2017, KEN RESEARCH All rights reserved.

Compare